The global wearable injectors market size was estimated to be USD 8.85 billion in 2023 and is expected to reach at USD 55.84 billion by 2034 with a CAGR of 18.23% during the forecast period 2024-2034. Increasing occurrence of chronic illnesses, rising geriatric population, heightened concerns about needle stick injuries, growing demand for continuous monitoring & home-based treatment, robust healthcare infrastructure, an uptick in lifestyle disorders, surge in regulatory approvals, growing strategic initiatives by leading market players such as partnerships, collaborations, mergers, & acquisitions within market players, and rising introduction of advanced wearable injectors for drug delivery are some of the key factors boosting the market growth.
Rising introduction of advanced wearable injectors for drug delivery is predicted to boost the market growth during the forecast period. Enhancing both patient and healthcare worker safety, wearable injectors eliminate the risks linked to conventional infusion and injection methods, including tasks such as drug preparation, needle insertion, covering, and needle disposal. Patients have the capability to self-administer medications subcutaneously at home using wearable injectors, mitigating the risk of needle stick injuries associated with intravenous injectables and parenteral administration. Consequently, market players are innovatively introducing wearable injectors for drug delivery. For instance, in June 2023, Stevanato has revealed the launch of the VertivaTM on-body delivery system in partnership with Thermo Fisher Scientific.
By type, on-body was the highest revenue-grossing segment in the global wearable injectors market in 2023 owing to their comfort when worn on the skin, specifically the stomach, along with their water-resistant properties, & the convenience they offer for at-home use, and growing launch of new products. For instance, in February 2022, AbbVie introduced the Skyrizi on-body injector for the management of Crohn's disease. Additionally, off-body is predicted to grow at fastest CAGR during the forecast period owing to the increasing investments in the advancement of enhanced off-body devices are addressing potential risks associated with their usage. These devices aim to eliminate issues such as painful removal, challenges with adhesive fitting to the skin, and concerns related to skin sensitivity or irritation.
By technology, spring-based was the highest revenue-grossing segment in the global wearable injectors market in 2023 owing to the patient accuracy in subcutaneous medicine administration is facilitated by the device's emphasis on ease of use, which involves pushing one or more buttons. Additionally, rotary pump is predicted to grow at fastest CAGR during the forecast period due to the enhanced convenience and the increasing trend of mergers and acquisitions among market participants. For instance, in February 2023, Insulet Corporation, a medical devices company, has acquired assets from Automated Glucose Control LLC (AGC), a leading industry player specializing in the advancement and commercialization of automated insulin delivery technology.
By application, oncology was the highest revenue-grossing segment in the global wearable injectors market in 2023 owing to the increasing incidence of cancer, a growing preference for self-administration of medication by patients, a rising trend towards patients independently administering their medication, and the continual introduction of new products. For instance, in May 2023, Coherus BioSciences, Inc. has declared the commercial availability of the single-dose (6mg/0.6mL), prefilled autoinjector version of UDENYCA (pegfilgrastim-cbqv) in the United States. Additionally, infectious disease is predicted to grow at the fastest CAGR during the forecast period owing to the rising occurrence of emerging infectious diseases and a growing demand for advanced drug delivery methods.
By end-user, home care was the highest revenue-grossing segment in the global wearable injectors market in 2023 owing to the demand for home-based healthcare is on the rise, prompting a need for advanced drug delivery devices that require minimal expertise, resulting in reduced hospitalization of patients, and surge in acquisitions within market players. For instance, in January 2023, The Sigi Patch Pump manufacturer, AMF Medical SA, has been acquired by Tandem Diabetes Care, Inc. Additionally, hospital is predicted to grow at fastest CAGR during the forecast period owing to the rising incidence of chronic diseases and an increasing influx of patients seeking treatment in hospitals. Patients undergoing oncology treatment often necessitate frequent medication administration, leading to regular hospital visits.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing prevalence of chronic & lifestyle-related diseases, the expansion of healthcare infrastructure, and growing investments made by major market players. For instance, in February 2022, Enable Injections has raised a funding round totaling USD 215 million to facilitate the advancement of its subcutaneous drug delivery system, enFuse. This system includes a wearable delivery disc and a mechanism for transferring the drug from its original container. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rise in supportive government initiatives promoting the utilization of medical devices like wearable injectors, coupled with a growing elderly population, an increase in healthcare spending, rising awareness about wearable injectors, and a notable uptick in mergers and acquisitions among market participants. For instance, in May 2023, Medtronic has announced its plans to acquire EOFlow, the company behind the creation of the wearable injector, EOPatch.
Rising introduction of advanced wearable injectors for drug delivery is predicted to boost the market growth during the forecast period. Enhancing both patient and healthcare worker safety, wearable injectors eliminate the risks linked to conventional infusion and injection methods, including tasks such as drug preparation, needle insertion, covering, and needle disposal. Patients have the capability to self-administer medications subcutaneously at home using wearable injectors, mitigating the risk of needle stick injuries associated with intravenous injectables and parenteral administration. Consequently, market players are innovatively introducing wearable injectors for drug delivery. For instance, in June 2023, Stevanato has revealed the launch of the VertivaTM on-body delivery system in partnership with Thermo Fisher Scientific.
By type, on-body was the highest revenue-grossing segment in the global wearable injectors market in 2023 owing to their comfort when worn on the skin, specifically the stomach, along with their water-resistant properties, & the convenience they offer for at-home use, and growing launch of new products. For instance, in February 2022, AbbVie introduced the Skyrizi on-body injector for the management of Crohn's disease. Additionally, off-body is predicted to grow at fastest CAGR during the forecast period owing to the increasing investments in the advancement of enhanced off-body devices are addressing potential risks associated with their usage. These devices aim to eliminate issues such as painful removal, challenges with adhesive fitting to the skin, and concerns related to skin sensitivity or irritation.
By technology, spring-based was the highest revenue-grossing segment in the global wearable injectors market in 2023 owing to the patient accuracy in subcutaneous medicine administration is facilitated by the device's emphasis on ease of use, which involves pushing one or more buttons. Additionally, rotary pump is predicted to grow at fastest CAGR during the forecast period due to the enhanced convenience and the increasing trend of mergers and acquisitions among market participants. For instance, in February 2023, Insulet Corporation, a medical devices company, has acquired assets from Automated Glucose Control LLC (AGC), a leading industry player specializing in the advancement and commercialization of automated insulin delivery technology.
By application, oncology was the highest revenue-grossing segment in the global wearable injectors market in 2023 owing to the increasing incidence of cancer, a growing preference for self-administration of medication by patients, a rising trend towards patients independently administering their medication, and the continual introduction of new products. For instance, in May 2023, Coherus BioSciences, Inc. has declared the commercial availability of the single-dose (6mg/0.6mL), prefilled autoinjector version of UDENYCA (pegfilgrastim-cbqv) in the United States. Additionally, infectious disease is predicted to grow at the fastest CAGR during the forecast period owing to the rising occurrence of emerging infectious diseases and a growing demand for advanced drug delivery methods.
By end-user, home care was the highest revenue-grossing segment in the global wearable injectors market in 2023 owing to the demand for home-based healthcare is on the rise, prompting a need for advanced drug delivery devices that require minimal expertise, resulting in reduced hospitalization of patients, and surge in acquisitions within market players. For instance, in January 2023, The Sigi Patch Pump manufacturer, AMF Medical SA, has been acquired by Tandem Diabetes Care, Inc. Additionally, hospital is predicted to grow at fastest CAGR during the forecast period owing to the rising incidence of chronic diseases and an increasing influx of patients seeking treatment in hospitals. Patients undergoing oncology treatment often necessitate frequent medication administration, leading to regular hospital visits.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing prevalence of chronic & lifestyle-related diseases, the expansion of healthcare infrastructure, and growing investments made by major market players. For instance, in February 2022, Enable Injections has raised a funding round totaling USD 215 million to facilitate the advancement of its subcutaneous drug delivery system, enFuse. This system includes a wearable delivery disc and a mechanism for transferring the drug from its original container. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rise in supportive government initiatives promoting the utilization of medical devices like wearable injectors, coupled with a growing elderly population, an increase in healthcare spending, rising awareness about wearable injectors, and a notable uptick in mergers and acquisitions among market participants. For instance, in May 2023, Medtronic has announced its plans to acquire EOFlow, the company behind the creation of the wearable injector, EOPatch.
Segmentation: Wearable Injectors Market Report 2023 - 2034
Wearable Injectors Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Off-body
- On-body
Wearable Injectors Market Analysis & Forecast by Technology 2023 - 2034 (Revenue USD Bn)
- Rotary Pump
- Motor-Driven
- Spring-based
- Expanding Battery
- Other
Wearable Injectors Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Cardiovascular Disease
- Autoimmune Disease
- Immunodeficiency
- Infectious Disease
- Oncology
- Others
Wearable Injectors Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Home Care
- Hospitals
- Clinics
- Others
Wearable Injectors Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Wearable Injectors Market: Type Estimates & Trend Analysis
8. Wearable Injectors Market: Technology Estimates & Trend Analysis
9. Wearable Injectors Market: Application Estimates & Trend Analysis
10. Wearable Injectors Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Wearable Injectors Market
13. Europe Global Wearable Injectors Market
14. Asia Pacific Global Wearable Injectors Market
15. Latin America Global Wearable Injectors Market
16. MEA Global Wearable Injectors Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- West Pharmaceutical Services Inc.
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services Inc.
- Steady Med Therapeutics Inc.
- BD
- Amgen Inc.
- CeQur Simplicity
- Insulet Corporation
- Unilife Corporation
- Enable Injections
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 8.85 Billion |
| Forecasted Market Value ( USD | $ 55.84 Billion |
| Compound Annual Growth Rate | 18.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
